Synthetic Lethality and PARP Inhibitors

Synthetic lethality is a genetic interaction in which the simultaneous loss of function of two genes (or one gene and one pharmacological target) results in cellular death, whereas inactivation of either gene alone remains compatible with cell viability. In precision oncology, synthetic lethality provides a general solution to the long-standing challenge of drugging loss-of-function tumor suppressor genes: because a deleted or truncated tumor suppressor protein cannot be directly reactivated by a small molecule, inhibiting a compensatory backup pathway selectively kills the mutant tumor cells while sparing normal host tissues that retain a functional copy of the tumor suppressor.

The phenomenon was first observed in Drosophila pseudoobscura by Calvin Bridges in 1922, named "synthetic lethality" by Theodosius Dobzhansky in 1946, and proposed as a framework for selective anticancer drug discovery by Leland Hartwell and Stephen Friend in 1997. In 2005, landmark back-to-back studies by Alan Ashworth (Nature, Farmer et al.) and Thomas Helleday (Nature, Bryant et al.) demonstrated that pharmacological inhibition of Poly(ADP-ribose) polymerase (PARP) exhibits up to 1,000-fold selective cytotoxicity against tumor cells carrying biallelic loss-of-function mutations in the breast and ovarian cancer susceptibility genes BRCA1 or BRCA2—establishing the first clinically validated synthetic lethal therapy.

Physiological Role of PARP1 in Single-Strand Break Repair

Human cells sustain tens of thousands of endogenous single-strand DNA breaks (SSBs) daily from reactive oxygen species, spontaneous base hydrolysis, and topoisomerase I cleavage intermediates. PARP1 (an abundant 113-kDa nuclear enzyme) and PARP2 act as first-responder molecular sensors of SSBs within the Base Excision Repair (BER) / single-strand break repair pathway.

When the N-terminal zinc-finger domains (Zn1, Zn2, Zn3) of PARP1 bind an exposed DNA nick, a conformational allosteric signal propagates through the tryptophan–glycine–arginine (WGR) domain to unfold the autoinhibitory helical subdomain (HD) of the C-terminal catalytic domain. Activated PARP1 consumes oxidized nicotinamide adenine dinucleotide (NAD⁺) as a substrate, cleaving the glycosidic bond to release nicotinamide and polymerizing negatively charged linear and branched poly(ADP-ribose) (PAR) chains (up to 200 ADP-ribose units) onto glutamate, aspartate, and serine residues of core histones and onto PARP1 itself (auto-PARylation). The dense polyanionic PAR scaffold serves two functions: (1) it relaxes local chromatin structure and recruits the scaffold protein XRCC1, DNA polymerase β, and DNA ligase III to seal the nick; and (2) strong electrostatic repulsion between the negatively charged PAR chains and the negatively charged phosphodiester DNA backbone triggers dissociation of PARP1 from the repaired DNA lesion, allowing the replication machinery to pass unimpeded.

Catalytic Inhibition vs. Allosteric PARP1–DNA Trapping

Clinical PARP inhibitors (PARPi)—including olaparib, niraparib, rucaparib, talazoparib, and veliparib—contain a carboxamide benzamide pharmacophore that mimics the nicotinamide moiety of NAD⁺. Rather than acting through simple catalytic depletion of BER, PARP inhibitors kill homologous-recombination-deficient (HRD) cells through a dual mechanism dominated by PARP–DNA trapping:

1. Catalytic NAD⁺ Competition: The inhibitor competitively occupies the NAD⁺ binding pocket in the C-terminal catalytic domain, blocking PAR chain synthesis and preventing auto-PARylation.
2. Allosteric Retention and PARP Trapping: Absence of negatively charged auto-PARylation chains—combined with drug-specific reverse allosteric signaling from the catalytic pocket back through the HD and WGR domains to the DNA-binding zinc fingers—locks the PARP1 protein onto the single-strand break as a bulky, cytotoxic PARP1–DNA nucleoprotein complex.

Across clinical inhibitors, catalytic IC₅₀ values lie within a narrow nanomolar range (1–5 nM), whereas PARP-trapping potency varies by more than 100-fold in the rank order:

Talazoparib ≫ Niraparib ≈ Olaparib ≈ Rucaparib ≫ Veliparib

This trapping hierarchy correlates directly with both single-agent cytotoxicity in BRCA-mutant cells and dose-limiting hematologic myelosuppression in patients, explaining why the clinical daily dose of talazoparib is 1 mg once daily compared to 600 mg/day (300 mg twice daily) for olaparib and 1,200 mg/day for rucaparib.

Replication Fork Collapse and Error-Prone NHEJ

During S phase, when a progressing DNA replication fork encounters a trapped PARP1–DNA complex or an unrepaired SSB, the replicative helicase/polymerase stalls and the lesion collapses into a one-ended double-strand break (DSB).

In normal host cells (which are wild-type or heterozygous BRCA1^+/− or BRCA2^+/−), the functional BRCA1–PALB2–BRCA2 complex mediates 5′-to-3′ DNA end resection, loads RAD51 recombinase filaments onto single-stranded DNA overhangs, and repairs the collapsed replication fork error-free via Homologous Recombination Repair (HRR) using the sister chromatid as a template.

In tumor cells that have undergone biallelic loss of BRCA1, BRCA2, PALB2, RAD51C, or RAD51D (typically a germline pathogenic variant paired with somatic loss of heterozygosity [LOH] of the second allele, in accordance with Knudson's two-hit hypothesis), HRR is non-functional. The collapsed replication fork is shunted into error-prone classical Non-Homologous End Joining (c-NHEJ) (mediated by 53BP1, Ku70/80, and DNA-PKcs) or Theta-Mediated End Joining (TMEJ / MMEJ) (mediated by DNA Polymerase θ [POLQ]). Ligating one-ended DSBs across non-homologous chromosomes generates dicentric chromosomes, asymmetric chromatid radial structures, mitotic catastrophe, and apoptosis.

Homologous Recombination Deficiency (HRD) Companion Diagnostics

Beyond germline or somatic BRCA1/2 mutations, tumors can acquire an HRD phenotype ("BRCAness") through promoter hypermethylation of BRCA1 or RAD51C or mutations in other HRR pathway genes. Because chronic reliance on error-prone repair leaves permanent structural signatures across the tumor genome, clinical companion diagnostics (such as the Myriad myChoice CDx assay) quantify a composite Genomic Instability Score (GIS) by summing three chromosomal metrics:

1. Loss of Heterozygosity (LOH): Number of subchromosomal LOH regions longer than 15 Mb but shorter than an entire chromosome.
2. Telomeric Allelic Imbalance (TAI): Number of regions with allelic imbalance extending to the subtelomere without crossing the centromere.
3. Large-Scale State Transitions (LST): Number of chromosomal breaks between adjacent regions of at least 10 Mb after filtering regions ≤3 Mb.

A composite GIS score ≥ 42 (or presence of a pathogenic BRCA1/2 mutation) defines HRD positivity in high-grade serous ovarian carcinoma, predicting substantial progression-free survival benefit from olaparib plus bevacizumab (PAOLA-1) or niraparib (PRIMA).

Clinical Mechanisms of PARP Inhibitor Resistance

Under prolonged PARP inhibitor therapy, tumors evolve resistance through four principal pathways:

• Somatic Reading-Frame Reversion Mutations: Secondary somatic indels in BRCA1, BRCA2, PALB2, or RAD51C/D—detectable in plasma ctDNA—excise the original frameshift or nonsense mutation and restore the open reading frame, re-establishing functional RAD51 loading and HRR proficiency (inducing cross-resistance to platinum chemotherapy).
• Loss of End-Protection (53BP1–Shieldin–CST Complex): In BRCA1-deficient cells (where BRCA1 is normally required to antagonize 53BP1 and promote CtIP/MRN end resection), somatic loss of 53BP1 (TP53BP1), REV7, or the Shieldin complex (SHLD1/2/3) removes the barrier to 5′ end resection, allowing BRCA2 and RAD51 to perform HRR without BRCA1.
• PARP1 Mutations and Replication Fork Stabilization: Point mutations in the PARP1 zinc-finger DNA-binding domains (e.g., p.Arg591Cys) abolish PARP1 trapping, while loss of PTIP or CHD4 prevents MRE11 nuclease degradation of stalled replication forks.
• Drug Efflux: Upregulation of the ABCB1 (P-glycoprotein / MDR1) ATP-binding cassette transporter actively pumps olaparib and rucaparib out of the cytoplasm.

Why are normal tissues of BRCA1 or BRCA2 mutation carriers spared by PARP inhibitors?

Patients with hereditary breast and ovarian cancer syndrome inherit one mutant BRCA1/2 allele and one functional wild-type allele in every somatic cell (BRCA^+/−). A single wild-type allele produces sufficient BRCA protein to sustain Homologous Recombination Repair in normal tissues. Only the neoplastic cells—which have lost the remaining wild-type allele via somatic loss of heterozygosity (BRCA^−/−)—are HRR-deficient and undergo synthetic lethality. Why hematologic toxicity (anemia) still occurs with first-generation PARPi is largely due to off-target inhibition of PARP2, which is required for erythroid progenitor survival; next-generation PARP1-selective inhibitors (such as saruparib) spare PARP2 to widen the therapeutic index.

Can BRCA-wild-type tumors respond to PARP inhibitors?

Yes. Approximately 50% of high-grade serous ovarian carcinomas exhibit Homologous Recombination Deficiency: ~20%–25% carry germline or somatic BRCA1/2 mutations, while another ~25% harbor epigenetic BRCA1/RAD51C promoter methylation or loss of PALB2, RAD51C, or RAD51D, detected via HRD genomic scar scores (GIS ≥ 42).

What is DNA Polymerase θ (Pol θ) synthetic lethality?

When HRR-deficient (BRCA1/2^−/−) cells lose classical HRR, they become hyper-dependent on DNA Polymerase θ (POLQ)-mediated Theta-Mediated End Joining (TMEJ) to repair DSBs. Small-molecule Pol θ helicase or polymerase inhibitors (such as novobiocin or ART558) are therefore synthetically lethal with both BRCA1/2 loss and 53BP1/Shieldin-loss PARPi-resistant tumors.

1. Farmer, H., McCabe, N., Lord, C. J., et al. (2005). "Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy." Nature, 434(7035), 917–921. https://doi.org/10.1038/nature03445
2. Bryant, H. E., Schultz, N., Thomas, H. D., et al. (2005). "Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase." Nature, 434(7035), 913–917. https://doi.org/10.1038/nature03443
3. Murai, J., Huang, S. Y. N., Das, B. B., et al. (2012). "Trapping of PARP1 and PARP2 by clinical PARP inhibitors." Cancer Research, 72(21), 5588–5599. https://doi.org/10.1158/0008-5472.CAN-12-2753
4. Lord, C. J., & Ashworth, A. (2017). "PARP inhibitors: Synthetic lethality in the clinic." Science, 355(6330), 1152–1158. https://doi.org/10.1126/science.aam7344